Hospital Universitario De Jaen — Clinical Trial Site

126 Registered trials

53 Currently recruiting

Organisation

Hospital Universitario De Jaen

Location

Jaen, Spain

Identifier

ORG-100041196

Address

Avenida Del Ejercito Espanol 10, 23007, Spain

Departments

034028: Oncología Médica
1201: Oncología Médica
1212:Oncología Médica
Allergy
Angiology and Vascular Sugery
Cardiology
Cardiology department
Dermatology
Endocrinología y Nutrición
ESP011:Oncología Médica
Hematología
Hematology
Hospital Universitario de Jaén
HU de Jaén_Cardiología
Infectious Diseases
Internal Medicine
Medica Oncology
Medical Oncology
Medical Oncology Department
Medicina Interna
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology department
Oncology service
Servicio de Angiología y Cirugía vascular
Servicio de Cardiologia
Servicio de Oncologia
Servicio de Oncología Médica
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
UGC Cuidados Intensivos
Unidad de Gestion Clinica de Oncologia Medica
Urology
Vascular Risk

Clinical trials at this site (126)

Search interface

Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended

2024-510967-41-00 Metastatic colorectal cancer 5 2018-09-21
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended

2023-509923-42-00 HER2- positive breast cancer 4 2017-07-06
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-506390-35-00 Patients with Advanced Solid Tumors 1 2017-04-19
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Noradrenaline plus placebo vs noradrenaline plus terlipressin for the treatment of septic shock Ended

2024-514149-12-00 Septic Shock 5 2024-06-26
Temocilin vs meropenem for the treatment of infections due to Enterobacteriales Ended

2023-508440-21-00 Infections due to Enterobacteriaceae 5 2024-05-21
Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Ended

2023-504153-12-00 Advanced or Metastatic Solid Tumors 4 2023-12-07
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c… Ended

2023-503627-26-00 Metastatic breast cancer 4 2023-09-28
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi… Ended

2022-501618-70-00 BRAF-V600 Mutant Solid Tumors including Melanoma, Non-s 7 2023-06-27
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08
Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization i… Ended

2023-504342-55-00 Cohort A: • Metastatic non-small cell lung carcinoma ( 10 2023-02-02
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 venous thromboembolism (VTE) in patients with gastroint 10 2022-09-13
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended

2023-506380-33-00 Early or Locally Advanced/ Inflammatory HER2-Positive B 5 2022-06-28
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended

2024-512052-38-00 Advanced triple negative breast cancer 9 2021-12-02
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic… Ended

2024-517251-12-00 Recurrent or metastatic head and neck squamous cell car 5 2021-11-02
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c… Ended

2024-514803-33-00 Non-small cell lung cancer (NSCLC) 4 2021-06-16
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03